Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 267

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Safety of a peanut oral immunotherapy protocol in children with peanut allergy

Open access
Hofmann, Alison M., Scurlock, Amy M., Jones, Stacie M., Palmer, Kricia P., Lokhnygina, Yuliya, Steele, Pamela H., Kamilaris, Janet, Burks, A. Wesley · 2009 · Journal of Allergy and Clinical Immunology

Abstract

Background Oral immunotherapy offers a promising therapeutic option for peanut allergy. Given that during oral immunotherapy an allergic patient ingests an allergen that could potentially cause a serious reaction, safety of oral immunotherapy is of particular concern. Objective The purpose of this study is to examine safety during the initial escalation day, build-up phase, and home dosing phase in subjects enrolled in a peanut oral immunotherapy study. Methods Skin, upper respiratory, chest and abdominal symptoms were recorded with initial escalation day and build-up phase dosings. Subjects also maintained daily diaries detailing symptoms after each home dosing. A statistical analysis of this data was performed. Results Twenty of 28 patients completed all phases of the study. During the initial escalation day, upper respiratory (79%) and abdominal (68%) symptoms were the most likely symptoms experienced. The risk of mild wheezing during the initial escalation day was 18%. The probability of having any symptoms after a build-up phase dose was 46%, with a risk of 29% for upper respiratory symptoms and 24% for skin symptoms. The risk of reaction with any home dose was 3.5%. Upper respiratory (1.2%) and skin (1.1%) were the most likely symptoms after home doses. Treatment was given with 0.7% of home doses. Two subjects received epinephrine after one home dose each. Conclusions Subjects were more likely to have significant allergic symptoms during the initial escalation day when they were in a closely monitored setting than during other phases of the study. Allergic reactions with home doses were rare.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jaci.2009.03.045

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 267

Metadata

Authors
Hofmann, A. M., Scurlock, A. M., Jones, S. M., Palmer, K. P., Lokhnygina, Y., Steele, P. H., Kamilaris, J., & Burks, A. W.
Venue
Journal of Allergy and Clinical Immunology
Publisher
Elsevier BV
Published
2009-08
Volume
124
Issue
2
Pages
286-291.e6
ISSN
0091-6749 (ISSN-L)
OpenAlex
W2152522850
Cited by
267
References
20
FWCI
19.69
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety of a peanut oral immunotherapy protocol in children with peanut allergy. https://app.cochat.ai/papers/10.1016/j.jaci.2009.03.045
The paper
Hofmann, A. M., Scurlock, A. M., Jones, S. M., Palmer, K. P., Lokhnygina, Y., Steele, P. H., Kamilaris, J., & Burks, A. W. (2009). Safety of a peanut oral immunotherapy protocol in children with peanut allergy. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2009.03.045

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.